Should You Buy Class B Shares of Berkshire Hathaway While They're Below $500?

Warren Buffett will step down as Berkshire Hathaway CEO after roughly six decades, handing day-to-day control to Greg Abel while remaining chairman; Todd Combs has also departed senior leadership. Berkshire enters the transition with sizable financial firepower—insurance operations produced $22.6 billion of earnings in 2024, the equities portfolio exceeds $300 billion, and cash, cash equivalents and short-term U.S. Treasuries totaled over $377 billion as of 2025 Q3—and Class B shares traded near $497 (Class A ≈ $744,100) at about 185% of tangible book value (10-year average 196%). The combination of a fortress balance sheet and diversified, large-scale businesses supports confidence in steady long-term returns, though near-term investor sentiment may be affected by Buffett’s departure.

Analysis

Market structure: Berkshire (BRK.B ~$497, trading ~185% of TBV vs 10-year avg 196%) is positioned to benefit from continued insurance float, large cash ($377B) and a $300B equities book that can be redeployed. Near-term winners are diversified, cash-rich conglomerates and defensive industrials (rail, energy), while purely fee-for-service asset managers and small insurers without scale could lose relative investor flows. Supply/demand dynamics point to a short-term excess supply (retail de-risking from the Buffett era) but structurally constrained supply because A-shares are illiquid and management control remains centralized.

Risk assessment: Tail risks include a governance/strategy error under Greg Abel or capital deployment mistakes that re-rate the stock from 185% TBV to parity (~100% TBV, ~46% downside). Immediate (days) risk = volatility around transition headlines; short-term (weeks–months) = multiple contraction if insiders sell or earnings disappoint; long-term (years) = fundamentals likely intact given $22.6B insurance earnings but dependent on new CIO/portfolio stewards after Todd Combs departure. Hidden dependency: concentration risk in a few large equity positions (AAPL, BAC, CVX) and reputation-driven passive inflows; catalysts are any large M&A, 2026 shareholder letter, or material asset redeployment.

Trade implications: Direct: establish a measured core long (1–3% portfolio) in BRK.B beneath $500, adding to 2–4% if price drops to ~$420 (~150% TBV). Pair: long BRK.B vs short SPY (dollar-neutral 0.5–1%) to capture relative resilience; exit if BRK.B surpasses 196% TBV or SPY outperforms by >8% in 3 months. Options: buy 6–9 month puts 25–35% OTM as tail insurance, or sell 1–3 month covered calls (5–8% OTM) against new purchases to generate yield.

Contrarian angles: Consensus underweights management transition risk but overstates permanent loss of moat—company cash/insurance float is a structural advantage few peers can replicate, so a temporary multiple compression is a buying opportunity. History (post-founder transitions at large family-like firms) shows 6–18 month re-rating windows; if Abel announces disciplined capital deployment within 6 months, expect a recovery. Watch for the unintended consequence that rapid cash deployment into low-return deals could structurally damage ROIC and justify a deeper haircut than price implies.

Key Decisions for Investors

• Establish a 1–3% long position in BRK.B at market (≈$497); scale up to 2–4% if price falls to ≈$420 (target = ~150% TBV) and reassess after Abel’s first shareholder letter or a material cash deployment announcement within 6 months.
• Initiate a dollar-neutral pair: long BRK.B (1% portfolio) vs short SPY (0.5–1% equivalent) to express relative-value defensive tilt; close or rebalance if BRK.B outperforms SPY by >8% within 3 months or if BRK.B >196% TBV (~20% above current).
• Buy 6–9 month BRK.B puts 25–35% OTM (small hedge sized to 0.5% portfolio risk) to protect against a tail re-rating to TBV parity; alternatively, sell 1–3 month covered calls 5–8% OTM on newly established shares to generate 3–6% annualized yield while awaiting clarity.
• Reduce concentrated high-growth exposure (e.g., trim NVDA/AAPL positions by 2–4% combined) and redeploy into BRK.B or selective industrials (UNP, CSX) over the next 2–6 weeks to lower portfolio cyclicality and capture the conglomerate discount if re-rating occurs.
• Monitor three near-term catalysts for adding risk: (1) Abel’s first capital allocation guidance (within 90 days), (2) any >$20B cash deployment/M&A, and (3) Q1 2026 insurance underwriting results; add to longs if guidance is disciplined and deployments exceed 20% ROIC hurdle or buybacks are announced.